Valneva SE Sets 2025 Results Release, Eyes Major Lyme‑Disease Vaccine MilestoneValneva SE to report 2025 results on March 18 2026 amid VLA15 Phase‑3 data release, aiming for first commercial Lyme vaccine launch before 2028.Valneva SE Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 09/03/2026, 18:04 3 minutes to read